ANI Pharmaceuticals: Tezruly Just Approved, 2 More NDAs Under Review And Alimera Science Acquisition Could Triple Revenue By 2028

Fokusiert/iStock via Getty ImagesAni Pharmaceuticals (NASDAQ:ANIP) had not provided any details on their three 505(b)(2) NDA submissions currently being reviewed by the FDA. Therefore, analysts have excluded their revenue potential in assessing ANIP’s growth outlook. On ANIP has yet to announce that on July 29, 2024 the FDA approved Tezruly as the first oral solution of terazosin. Tezruly's related patent expires February 1, 2041. Based on ANIP’s SEC filings, patent applications and clinical trial infor ...